NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Mediclinic and rivals press Abu Dhabi to rethink healthcare reform

Published 02/03/2017, 10:42
Updated 02/03/2017, 10:51
© Reuters. The Mediclinic logo is seen in Dubai
NMC
-
MDCM
-

By Stanley Carvalho

ABU DHABI (Reuters) - International healthcare operator Mediclinic (L:MDCM) is lobbying the Abu Dhabi government to rethink a change in medical insurance rules that has damaged its business after it bet big on acquiring Al Noor Hospitals, its regional CEO told Reuters.

At least two other healthcare companies operating in Abu Dhabi are also in talks with authorities, seeking a reversal or amendment to the reform that reduces state insurance coverage for citizens using private hospitals, according to two industry sources who declined to be named due to the sensitivity of the matter.

Abu Dhabi has cut insurance coverage under its Thiqa plan to 80 percent from 100 percent, meaning patients have to pay 20 percent of bills if they seek treatment at private hospitals.

The rule, which does not apply to government hospitals, was introduced last July - at the worst possible time for Mediclinic as it had just bought Abu Dhabi private hospital group Al Noor for about $1.7 billion.

The London and Johannesburg-listed company's experience illustrates the business risks in the Gulf's oil-exporting countries as low crude prices dampen economies and strain state finances.

The firm has begun lobbying the state Health Authority of Abu Dhabi over the Thiqa change, David Hadley, chief executive of Mediclinic Middle East, told Reuters in an interview.

"Other providers have done the same," said Hadley, adding that the reform had channelled patients to government hospitals. "We don't have a problem with the policy on co-payments as long as it applies to the entire industry."

One of the industry sources said that although authorities did not want to be seen as giving in to pressure in any way, the policy might be adjusted again around the end of this year - partly because reduced Thiqa coverage had led to higher costs at state hospitals, hitting the government's budget.

The Health Authority of Abu Dhabi did not respond to requests for comment about the private sector's discontent with the Thiqa change or whether it planned to scrap the reform or extend it to all hospitals.

It has previously said that the rule change would contribute to its efforts to increase efficiency, standardise operations and increase the sector's financial viability for the benefit of patients and the healthcare system as a whole.

'MULTITUDE OF HEADWINDS'

By many measures, the Gulf is an attractive destination for foreign healthcare providers; incomes are high and growing populations are burdened with some of the world's highest levels of lifestyle diseases, such as diabetes.

Encouraged by such trends, Mediclinic, which has 73 hospitals and 43 clinics across South Africa, Namibia, Switzerland and the UAE, bought Al Noor last year. But since the Thiqa change, Al Noor's in-patient volumes have dropped 38 percent and out-patient volumes by 43 percent, Hadley said.

To compound Mediclinic's problems, at around the same time as the reform, competition intensified in Abu Dhabi with three new players entering the sector, while thousands of expatriates and their families left because of job losses in a slowing economy. Also, 147 doctors out of 600 left Al Noor, many to join new hospitals in the area, and new doctors had to be hired.

"We were hit by a multitude of headwinds. I think it was the timing - we couldn't have predicted. It is going to be a challenging year," said Hadley.

Mediclinic's London-listed shares have dropped 8 percent since the company issued a profit warning for its Middle East business last week.

While timing played its part, other factors might also have contributed to the company's struggles in the region, however.

"In the long-term it will probably be clear that Mediclinic overpaid for the Al Noor acquisition," said Neil Brown, analyst at Electus, a South Africa-based fund manager.

"However, at these Mediclinic share price levels of 120 rand, which are now around 40 percent lower than mid-2016 when the above-mentioned rules changed in Abu Dhabi, we believe that Mediclinic is attractively priced for longer-term investors."

'NEED FOR A CORRECTION'

Mediclinic has not diversified across the region as broadly as some rivals to share out its risk.

Its stock performance stands in stark contrast to rival NMC Health (L:NMC), which has seen its shares rise almost 13 percent year-to-date, according to Thomson Reuters data.

NMC, one of the oldest healthcare players in Abu Dhabi, has operations in seven emirates of the UAE as well as Saudi Arabia and Qatar, while Mediclinic has operations in just Abu Dhabi and Dubai.

Also, some rival companies say they disagree that the Thiqa change is negative for the private sector.

"It is a measure to manage over-utilisation and over-diagnosis. When coverage is free, no one cares," said Prasanth Manghat, deputy CEO of NMC Health.

Shamsheer Vayalil, managing director of VPS Healthcare, said: "Unnecessary medical visits have stopped since the new policy took effect. There was a need for a correction."

© Reuters. The Mediclinic logo is seen in Dubai

Mediclinic aims to complete the Al Noor integration and rebranding by the end of this year. A total of 432 jobs at Al Noor were cut in 2016 with another 511 to go in the next few months, said Hadley. Of the planned lay-offs, 183 jobs relate to the closure of small facilities and clinics, including one in Oman which was uneconomic, he said.

(Additional Reporting by Hadeel al Sayegh; Editing by Pravin Char)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.